Homepage
Author:
eXoZymes
Posted Date:
June 17, 2026
eXoZymes Inc. Announces Closing of $6 Million Public Offering
eXoZymes
June 17, 2026
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
eXoZymes
June 8, 2026
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
eXoZymes
May 7, 2026
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
eXoZymes
April 10, 2026
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
eXoZymes
March 31, 2026
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability
eXoZymes
March 18, 2026
eXoZymes’ CCO Damien Perriman to Present a NCT Solution at Next Week’s MISTA Symposium
eXoZymes
March 12, 2026
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
eXoZymes
February 10, 2026
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
eXoZymes
January 30, 2026
